Latest & greatest articles for prednisolone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prednisolone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prednisolone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prednisolone

41. 5-day and 3-day oral prednisolone did not differ for asthma control in children who had acute asthma exacerbations

5-day and 3-day oral prednisolone did not differ for asthma control in children who had acute asthma exacerbations 5-day and 3-day oral prednisolone did not differ for asthma control in children who had acute asthma exacerbations | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here 5-day and 3-day oral prednisolone did not differ for asthma control in children who had acute asthma exacerbations Article Text Therapeutics 5-day and 3-day oral prednisolone did not differ for asthma control in children who had acute asthma exacerbations Statistics from

Evidence-Based Medicine (Requires free registration)2009

42. Oral prednisolone for preschool children with acute virus-induced wheezing.

Oral prednisolone for preschool children with acute virus-induced wheezing. 19164186 2009 01 23 2009 01 27 2013 11 21 1533-4406 360 4 2009 Jan 22 The New England journal of medicine N. Engl. J. Med. Oral prednisolone for preschool children with acute virus-induced wheezing. 329-38 10.1056/NEJMoa0804897 Attacks of wheezing induced by upper respiratory viral infections are common in preschool children between the ages of 10 months and 6 years. A short course of oral prednisolone is widely used (...) to treat preschool children with wheezing who present to a hospital, but there is conflicting evidence regarding its efficacy in this age group. We conducted a randomized, double-blind, placebo-controlled trial comparing a 5-day course of oral prednisolone (10 mg once a day for children 10 to 24 months of age and 20 mg once a day for older children) with placebo in 700 children between the ages of 10 months and 60 months. The children presented to three hospitals in England with an attack of wheezing

NEJM2009

43. Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial

Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial 18849193 2008 10 22 2008 12 01 2014 08 15 1474-4422 7 11 2008 Nov The Lancet. Neurology Lancet Neurol Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. 993-1000 10.1016/S1474-4422(08)70221-7 Previous trials of corticosteroid or antiviral treatments for Bell's palsy have been underpowered or have had insufficient follow (...) -up. The aim of this study was to compare the short-term and long-term effects of prednisolone and valaciclovir in the recovery of the affected facial nerve in a large number of patients. In this randomised, double-blind, placebo-controlled, multicentre trial, patients aged 18 to 75 years who sought care directly or were referred from emergency departments or general practitioners within 72 h of onset of acute, unilateral, peripheral facial palsy, between May, 2001, and September, 2006, were

EvidenceUpdates2008

44. Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial

Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial 17573408 2008 03 05 2008 04 09 2014 11 20 1468-2044 93 3 2008 Mar Archives of disease in childhood Arch. Dis. Child. Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial. 226-8 Relapses of nephrotic syndrome are often triggered by viral upper respiratory tract (...) infections (URTIs), possibly mediated by cytokine release. To test, in a randomised double-blind placebo-controlled crossover trial, the hypothesis that a small short-term increase in the dose of prednisolone will reduce the release of cytokines and thereby reduce the risk of relapse. Sequential patients receiving low-dose (<0.6 mg/kg) prednisolone on alternate days as maintenance therapy were recruited. At the first sign of a presumed viral URTI, all children were examined and randomly allocated to take

EvidenceUpdates2008

45. Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis

Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis 17988236 2008 01 09 2008 04 11 2016 11 22 1365-2036 27 3 2008 Feb 01 Alimentary pharmacology & therapeutics Aliment. Pharmacol. Ther. Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis. 228-40 Systemic corticosteroids are effective in ulcerative colitis but commonly cause side effects. To compare the safety (...) and efficacy of a sparingly absorbed formulation of prednisolone metasulfobenzoate (Predocol) with a conventional tapering course of oral prednisolone. In a double-blind randomized study, 59 active ulcerative colitis patients received Predocol 40 mg/day for 6 months, 61 received Predocol 60 mg/day for 6 months and 61 received prednisolone 40 mg/day for 2 weeks, tapered to week 8, followed by placebo until 6 months. Steroid-related side effects assessed using a 10-cm visual analogue scale were fewer at 2

EvidenceUpdates2008

46. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma Hornberger J, Reyes C, Lubeck D, Valente N Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of rituximab (R) added to cyclophosphamide, vincristine, and prednisolone (CVP) as a first-line treatment for advanced follicular lymphoma (AFL), in adult patients with Ann Arbor Stage III or IV follicular non-Hodgkin lymphoma. The authors

NHS Economic Evaluation Database.2008

47. Oral prednisolone was not inferior to intravenous prednisolone for treatment failure in chronic obstructive pulmonary disease exacerbation

Oral prednisolone was not inferior to intravenous prednisolone for treatment failure in chronic obstructive pulmonary disease exacerbation Oral prednisolone was not inferior to intravenous prednisolone for treatment failure in chronic obstructive pulmonary disease exacerbation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral prednisolone was not inferior to intravenous prednisolone for treatment failure in chronic obstructive pulmonary disease exacerbation Article Text Therapeutics Oral prednisolone was not inferior to intravenous prednisolone

Evidence-Based Medicine (Requires free registration)2008

48. Early treatment with prednisolone, but not acyclovir, was effective in Bell’s palsy

Early treatment with prednisolone, but not acyclovir, was effective in Bell’s palsy Early treatment with prednisolone, but not acyclovir, was effective in Bell’s palsy | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Early treatment with prednisolone, but not acyclovir, was effective in Bell’s palsy Article Text Therapeutics Early treatment with prednisolone, but not acyclovir, was effective in Bell’s palsy Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all of this article

Evidence-Based Medicine (Requires free registration)2008

49. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial.

Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. 18514729 2008 06 02 2008 06 23 2015 06 16 1474-547X 371 9627 2008 May 31 Lancet (London, England) Lancet Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. 1854-60 10.1016/S0140-6736(08)60799-0 Non-steroidal anti-inflammatory drugs and colchicine used to treat gout arthritis have gastrointestinal, renal (...) , and cardiovascular adverse effects. Systemic corticosteroids might be a beneficial alternative. We investigated equivalence of naproxen and prednisolone in primary care. We did a randomised clinical trial to test equivalence of prednisolone and naproxen for the treatment of monoarticular gout. Primary-care patients with gout confirmed by presence of monosodium urate crystals were eligible. 120 patients were randomly assigned with computer-generated randomisation to receive either prednisolone (35 mg once a day

Lancet2008

50. Prednisolone plus a disease modifying antirheumatic drug improved outcomes in early rheumatoid arthritis

Prednisolone plus a disease modifying antirheumatic drug improved outcomes in early rheumatoid arthritis Prednisolone plus a disease modifying antirheumatic drug improved outcomes in early rheumatoid arthritis | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Prednisolone plus a disease modifying antirheumatic drug improved outcomes in early rheumatoid arthritis Article Text Therapeutics Prednisolone plus a disease modifying antirheumatic drug improved outcomes in early rheumatoid arthritis Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2007

51. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer Journals Library An error has occurred in processing the XML

NIHR HTA programme2007

52. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer A systematic review and economic model of the clinical (...) effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer S, Riemsma R CRD summary This well-conducted review concluded that docetaxel plus prednisone appears to be the most effective treatment for men with metastatic hormone-refractory prostate cancer. The review was based partially on an indirect comparison of treatments

DARE.2007

53. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. A systematic review and economic model of the clinical (...) effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer S, Riemsma R. Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Collins R, Fenwick E, Trowman R, Perard R

Health Technology Assessment (HTA) Database.2007

54. Prednisolone plus paracetamol (acetaminophen) was as effective as indomethacin plus paracetamol but had fewer adverse effects in acute gout-like arthritis

Prednisolone plus paracetamol (acetaminophen) was as effective as indomethacin plus paracetamol but had fewer adverse effects in acute gout-like arthritis Prednisolone plus paracetamol (acetaminophen) was as effective as indomethacin plus paracetamol but had fewer adverse effects in acute gout-like arthritis | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Prednisolone plus paracetamol (acetaminophen) was as effective as indomethacin plus paracetamol but had fewer adverse effects in acute gout-like arthritis Article Text Therapeutics Prednisolone plus

Evidence-Based Medicine (Requires free registration)2007

55. Early treatment with prednisolone or acyclovir in Bell's palsy.

Early treatment with prednisolone or acyclovir in Bell's palsy. 17942873 2007 10 18 2007 10 25 2013 11 21 1533-4406 357 16 2007 Oct 18 The New England journal of medicine N. Engl. J. Med. Early treatment with prednisolone or acyclovir in Bell's palsy. 1598-607 Corticosteroids and antiviral agents are widely used to treat the early stages of idiopathic facial paralysis (i.e., Bell's palsy), but their effectiveness is uncertain. We conducted a double-blind, placebo-controlled, randomized (...) , factorial trial involving patients with Bell's palsy who were recruited within 72 hours after the onset of symptoms. Patients were randomly assigned to receive 10 days of treatment with prednisolone, acyclovir, both agents, or placebo. The primary outcome was recovery of facial function, as rated on the House-Brackmann scale. Secondary outcomes included quality of life, appearance, and pain. Final outcomes were assessed for 496 of 551 patients who underwent randomization. At 3 months, the proportions

NEJM2007

56. Oral prednisolone reduced exacerbation of symptoms in children with virally induced lower airway disease

Oral prednisolone reduced exacerbation of symptoms in children with virally induced lower airway disease Oral prednisolone reduced exacerbation of symptoms in children with virally induced lower airway disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral prednisolone reduced exacerbation of symptoms in children with virally induced lower airway disease Article Text Therapeutics Oral prednisolone reduced exacerbation of symptoms in children with virally induced lower airway disease Free Elaine E Wang , MD, CM, MSc Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2005

57. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial.

The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. 15541450 2004 11 15 2004 12 07 2015 06 16 1474-547X 364 9447 2004 Nov 13-19 Lancet (London, England) Lancet The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. 1773-8 Infantile spasms, which comprise a severe infantile seizure disorder, have (...) a high morbidity and are difficult to treat. Hormonal treatments (adrenocorticotropic hormone and prednisolone) have been the main therapy for decades, although little evidence supports their use. Vigabatrin has been recorded to have a beneficial effect in this disorder. We aimed to compare the effects of vigabatrin with those of prednisolone and tetracosactide in the treatment of infantile spasms. The United Kingdom Infantile Spasms Study assessed these treatments in a multicentre, randomised

Lancet2004

58. Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients

Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients Holmes M, Chilcott J, Walters S, Whitby S (...) treatment strategies included: everolimus (Certican, Novartis Pharma AG, Basel, Switzerland) 1.5 mg; everolimus 3 mg; mycophenolate mofetil (MMF) (CellCept, Roche Pharmaceuticals, Basel, Switzerland). The first dose of study medication was given within 48 hours of surgery, after which medication was given twice daily. All patients received cyclosporine (CsA) micro-emulsion (Neoral, Novartis AG) and prednisolone. Patients with suspected acute rejection underwent renal biopsy and were treated

NHS Economic Evaluation Database.2004

59. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy

Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy McCrone P, Chisholm D, Knapp M, Hughes R, Comi G, Dalakas M C, Illa I, Kilindireas C, Nobile-Orazio E (...) , Swan A, Van den Bergh P, Willison H J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two 6-week treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) were examined. The treatments were prednisolone (PRE

NHS Economic Evaluation Database.2003

60. Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial.

Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. 14602435 2003 11 06 2004 01 21 2015 06 16 1474-547X 362 9394 2003 Nov 01 Lancet (London, England) Lancet Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. 1433-8 Episodic wheeze triggered by viral colds is common in children aged between 1 and 5 years (preschool viral (...) wheeze). Most affected children are asymptomatic by age 6 years. Persistence of wheeze is associated with above-average systemic eosinophil priming. Use of parental-initiated oral prednisolone is recommended at the first sign of preschool viral wheeze. However, evidence for this treatment strategy is conflicting. We therefore aimed to assess the efficacy of a short course of oral prednisolone for preschool viral wheeze, with stratification for systemic eosinophil priming. Children aged 1-5 years

Lancet2003